Article Sidebar

PDF
Date Published: 05/07/2023
Abstract Views: 286
Views PDF: 186
DOI: https://doi.org/10.51298/vmj.v527i2.5841
Issue
Vol. 527 No. 2 (2023)
Section
Các bài báo
How to Cite
Nguyễn, Đức T., Nguyễn, T. T., Mã, T. Ánh, & Nguyễn, Q. H. (2023). EVALUATION OF CLINICAL OUTCOMES OF DECITABINE TREATMENT FOR MYELODYSPLASTIC SYNDROME PATINENTS AT THE THAI NGUYEN INTERNETIONAL HOSPITAL. Vietnam Medical Journal, 527(2). https://doi.org/10.51298/vmj.v527i2.5841

EVALUATION OF CLINICAL OUTCOMES OF DECITABINE TREATMENT FOR MYELODYSPLASTIC SYNDROME PATINENTS AT THE THAI NGUYEN INTERNETIONAL HOSPITAL

Đức Thắng Nguyễn1,, Thế Tùng Nguyễn1, Thị Ánh Mã2, Quang Hảo Nguyễn2
1 Thai Nguyen University Of Medicine And Pharmacy
2 Thai Nguyen Central Hospital

Main Article Content

Abstract

Objectives: Evaluation of clinical outcomes of Decitabine treatment for MDS patients and commom adverse events of Decitabine. Subjects and methods: 32 MDS patients have been diagnosed and treated at the Thai Nguyen Internetional Hospital. Results: 32 patients who were treated with Decitabine achieved a significantly including 46,9% complete responses and 25% partial responses. 9.4% of patients progressed to acute leukemia. The most common adverse effects included myelosuppression (neutropenia 27,9%, anemia 18,7% and thrombocytopenia 40,6%), constipation 31,2%, vomiting 28,1%, cough 21,8%, fever 18,7%, diarrhea 15,6%, and pneumonia 15,6%. Conclusion: Decitabine was found to be clinically effective in the treatment of patients with both lower-risk group and higher-risk group MDS, provided durable responses

Article Details

Keywords

RLST, MDS, Decitabine

References

1. Jung, K. S., Kim, Y.-J., Kim, Y.-K., Park, S. K., Kim, H. G., Kim, S. J.,… Jang, J. H. (2019). Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Clinical Lymphoma Myeloma and Leukemia, 19(10), 656–664.
2. Rollison, D. E., Howlader, N., Smith, M. T., Strom, S. S., Merritt, W. D., Ries, L. A.,… List, A. F. (2008). Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.Blood, 112(1), 45–52.
3. What Are Myelodysplastic Syndromes? | American Cancer Society. (n.d.). Retrieved August 11, 2020, from https://www.cancer.org/ cancer/ myelodysplastic-syndrome/about/what-is-mds.html
4. Hong, M., & He, G. (2017). The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes.Journal of Translational Internal Medicine, 5(3), 139–143.
5. Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G.,… Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood, 89(6), 2079–2088.
6. Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F.,… Haase, D. (2012). Revised International Prognostic Scoring System for Myelodysplastic Syndromes.Blood, 120(12), 2454–2465.
7. Montalban-Bravo, G., & Garcia-Manero, G. (2018). Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. American Journal of Hematology, 93(1), 129–147.
8. Steensma, D. P. (2018). Myelodysplastic syndromes current treatment algorithm 2018.Blood Cancer Journal, 8(5), 47.